Skip to Main Content

Paper Details

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Neurol Res Pract
13
2022
Author NameAffiliation
Ghazaleh TabatabaiUniversity Hospital Tubingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tubingen
Martin GlasDivision of Clinical Neurooncology, University Hospital Essen, University Duisburg-Essen
Guido ReifenbergerInstitute of Neuropathology, Heinrich Heine University Dusseldorf, University Hospital Dusseldorf
  • 1 - 3

Datasets

Release 1.2